Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.

Neta G, Anderson WF, Gilbert E, Berrington A.

Breast Cancer Res Treat. 2012 Feb;131(3):1021-7. doi: 10.1007/s10549-011-1820-8. Epub 2011 Oct 21.


Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.

Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI.

Breast Cancer Res Treat. 2012 Oct;135(3):849-55. doi: 10.1007/s10549-012-2183-5. Epub 2012 Aug 19.


Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.

Gao X, Fisher SG, Emami B.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1038-45.


The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status.

Schonfeld SJ, Curtis RE, Anderson WF, Berrington de González A.

Cancer Causes Control. 2012 Oct;23(10):1721-8. doi: 10.1007/s10552-012-0054-3. Epub 2012 Aug 24.


Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in the WECARE study.

Brooks JD, Boice JD Jr, Stovall M, Reiner AS, Bernstein L, John EM, Lynch CF, Mellemkjær L, Knight JA, Thomas DC, Haile RW, Smith SA, Capanu M, Bernstein JL, Shore RE; WECARE Collaborative Group.

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):917-24. doi: 10.1016/j.ijrobp.2012.01.047. Epub 2012 Apr 6.


Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.

Liu J, Jiang W, Mao K, An Y, Su F, Kim BY, Liu Q, Jacobs LK.

Breast Cancer Res Treat. 2015 Apr;150(2):439-45. doi: 10.1007/s10549-015-3315-5. Epub 2015 Mar 13.


Second solid cancers after radiotherapy for breast cancer in SEER cancer registries.

Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, Ron E.

Br J Cancer. 2010 Jan 5;102(1):220-6. doi: 10.1038/sj.bjc.6605435. Epub 2009 Nov 24.


Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.

Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, Czene K.

Breast Cancer Res Treat. 2012 Jul;134(2):793-800. doi: 10.1007/s10549-012-2096-3. Epub 2012 May 24.


Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

Nichols HB, Berrington de González A, Lacey JV Jr, Rosenberg PS, Anderson WF.

J Clin Oncol. 2011 Apr 20;29(12):1564-9. doi: 10.1200/JCO.2010.32.7395. Epub 2011 Mar 14.


Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F.

J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.


Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR.

JAMA. 2003 Jun 25;289(24):3254-63.


Second primary breast cancer occurrence according to hormone receptor status.

Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA.

J Natl Cancer Inst. 2009 Aug 5;101(15):1058-65. doi: 10.1093/jnci/djp181. Epub 2009 Jul 9.


Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?

Coradini D, Oriana S, Mariani L, Miceli R, Bresciani G, Marubini E, Di Fronzo G.

Eur J Cancer. 1998 May;34(6):825-30.


Breast cancer after treatment of Hodgkin's disease.

Hancock SL, Tucker MA, Hoppe RT.

J Natl Cancer Inst. 1993 Jan 6;85(1):25-31.


Body mass index and risk of second primary breast cancer: the WECARE Study.

Brooks JD, John EM, Mellemkjær L, Reiner AS, Malone KE, Lynch CF, Figueiredo JC, Haile RW, Shore RE; WECARE Study Collaborative Group, Bernstein JL, Bernstein L.

Breast Cancer Res Treat. 2012 Jan;131(2):571-80. doi: 10.1007/s10549-011-1743-4. Epub 2011 Sep 3.


Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer.

Li CI, Daling JR, Porter PL, Tang MT, Malone KE.

J Clin Oncol. 2009 Nov 10;27(32):5312-8. doi: 10.1200/JCO.2009.23.1597. Epub 2009 Sep 8.


Relationship between diabetes and risk of second primary contralateral breast cancer.

Li CI, Daling JR, Tang MT, Malone KE.

Breast Cancer Res Treat. 2011 Jan;125(2):545-51. doi: 10.1007/s10549-010-1035-4. Epub 2010 Jul 13.


Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.

Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, Malone KE, Mellemkjaer L, Borresen-Dale AL, Rosenstein BS, Teraoka SN, Diep AT, Smith SA, Capanu M, Reiner AS, Liang X, Gatti RA, Concannon P; WECARE Study Collaborative Group.

J Natl Cancer Inst. 2010 Apr 7;102(7):475-83. doi: 10.1093/jnci/djq055. Epub 2010 Mar 19.


Adjuvant radiotherapy and risk of contralateral breast cancer.

Storm HH, Andersson M, Boice JD Jr, Blettner M, Stovall M, Mouridsen HT, Dombernowsky P, Rose C, Jacobsen A, Pedersen M.

J Natl Cancer Inst. 1992 Aug 19;84(16):1245-50.


Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.

McCormack VA, Joffe M, van den Berg E, Broeze N, Silva Idos S, Romieu I, Jacobson JS, Neugut AI, Schüz J, Cubasch H.

Breast Cancer Res. 2013;15(5):R84.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk